Patent or proprietary medicine classification turns on brand connection marks, while pharmacopoeial status may support bulk drug exemption.

Cisplatin Injection was examined for central excise classification and exemption treatment. The product was held not to be a patent or proprietary medicine under Tariff Item 14E because the labels showed only the product name, strength, and manufacturer details, without any brand name, trade mark, monogram, or other proprietary mark indicating trade connection. It was therefore placed under Tariff Item 68. On exemption, the product was treated as eligible under Notification No. 234/82-C.E. as a bulk drug medicine because it conformed to pharmacopoeial standards, was used in cancer treatment, and later appeared in the United States Pharmacopoeia XXII 1990.

---

---

Issues: (i) Whether Cisplatin Injection was classifiable under Tariff Item 14E as a patent or proprietary medicine or under Tariff Item 68 of the Central Excise Tariff. (ii) Whether the product was entitled to exemption under Notification No. 234/82-C.E. as a bulk drug medicine.

Issue (i): Whether Cisplatin Injection was classifiable under Tariff Item 14E as a patent or proprietary medicine or under Tariff Item 68 of the Central Excise Tariff.

Analysis: Classification under Tariff Item 14E required not only that the medicine should be used for treatment or prevention of disease and bear a name not specified in a pharmacopoeial monograph or notified publication, but also that it should bear a brand name or other mark indicating a trade connection with the manufacturer. The labels on the product showed only the product name, strength, and the fact of manufacture by the appellants. They did not show any brand name, trade mark, monogram, or other proprietary mark. The Department did not establish that the product had the character of a patent or proprietary medicine.

Conclusion: Cisplatin Injection was not classifiable under Tariff Item 14E and fell under Tariff Item 68.

Issue (ii): Whether the product was entitled to exemption under Notification No. 234/82-C.E. as a bulk drug medicine.

Analysis: The product was shown to conform to pharmacopoeial standards, was used in the treatment of cancer, and had been subsequently included in the United States Pharmacopoeia XXII 1990. The exemption notification applied to bulk drugs medicines not elsewhere specified, and the later inclusion in a recognised pharmacopoeia supported eligibility. The Department failed to dislodge the claim to exemption on the facts proved.

Conclusion: Cisplatin Injection was eligible for exemption under Notification No. 234/82-C.E.

Final Conclusion: The classification adopted by the lower authorities was unsustainable, and the appellants succeeded in obtaining classification under Tariff Item 68 with the corresponding exemption benefit.

Ratio Decidendi: A medicine is not a patent or proprietary medicine unless it bears a brand name or other proprietary mark indicating a trade connection with the manufacturer, and subsequent inclusion in a recognised pharmacopoeia may support treatment of the product as a pharmacopoeial item for exemption purposes.

---